Isis Pharmaceuticals reports phase I study results

Tuesday, March 8, 2011 10:39 AM

Isis Pharmaceuticals announced the results from a phase I clinical trial in which ISIS-CRPRx produced statistical reductions in C-reactive protein (CRP) in the cohort with elevated CRP.  ISIS-CRPRx was well tolerated at doses up to 600 mg/week.  Isis plans to evaluate ISIS-CRPRx in phase II studies in indications that could provide early proof-of-concept in diseases with elevated CRP.  Isis plans to initially evaluate ISIS-CRPRx in multiple myeloma and rheumatoid arthritis, and then move to cardiovascular and other diseases.

The phase I study was a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS-CRPRx as well as to assess the initial effects of the drug on baseline CRP levels.  ISIS-CRPRx was evaluated in single and multiple doses ranging from 50 mg per week to 600 mg per week in 80 healthy volunteers.  In all but one cohort, Isis enrolled subjects who had normal CRP levels.  In the 600 mg per week multi-dose cohort, Isis enrolled eight subjects with elevated levels of CRP.  The subjects in this cohort had an average CRP level at baseline of approximately 3.0 mg/L. 

After only three weeks of dosing, the six subjects who received ISIS-CRPRx had an average CRP level of 0.76 mg/L, which is within the normal range of CRP and represents an average reduction of greater than 70% compared to placebo.  Subjects receiving placebo remained elevated above 3.0 mg/L.  In all subjects receiving the drug, it was well tolerated with no serious adverse events.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs